Clinical Trials

Search Results 1-5 of 5 for

Results filtered:
Study status: Open/Status Unknown

Edit search filters

MYELOMATCH: A Screening Study To Assign People With Myeloid Cancer To A Treatment Study Or Standard Of Care Treatment Within MyeloMATCH (MyeloMATCH Screening Trial)

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

MYELOMATCH: A Screening Study To Assign People With Myeloid Cancer To A Treatment Study Or Standard Of Care Treatment Within MyeloMATCH (MyeloMATCH Screening Trial)

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
2
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Scottsdale/Phoenix, AZ	Open for enrollment	View complete study & contact information
Jacksonville, FL	Open for enrollment
Rochester, MN	Open for enrollment

Print study details

Site IRB:
25-003191
NCT ID:
NCT05564390
Sponsor Protocol Number:
MYELOMATCH

A Study Of CTX-712 In Relapsed/Refractory Acute Myeloid Leukemia And Higher Risk Myelodysplastic Syndromes

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

A Study Of CTX-712 In Relapsed/Refractory Acute Myeloid Leukemia And Higher Risk Myelodysplastic Syndromes

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
1/2
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The goal of this phase 1/2 multicenter, open-label, single-arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS), or MDS/MPN (including CMML).

The phase 1 part of the study consists of sequential standard 3 + 3 dose escalation, where patients will receive ascending doses of CTX-712 to determine the recommended phase 2 dose (RP2D) for further clinical development. This is followed by initial expansion cohorts in AML and/or HR-MDS where patients will be treated with CTX-712 at the RP2D to gain further confidence in the selected dose level. Additional expansion cohorts may be initiated if considered necessary. After RP2D is determined, Drug-Drug-Interaction cohorts will be started.

The phase 2 part of the study will commence after the RP2D has been identified and confirmed and will evaluate therapeutic activity in R/R AML or R/R HR-MDS, in addition to confirmation of the safety profile.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Scottsdale/Phoenix, AZ	Contact us for the latest status	View complete study & contact information
Jacksonville, FL	Closed for enrollment
Rochester, MN	Contact us for the latest status

Print study details

Site IRB:
23-001738
NCT ID:
NCT05732103
Sponsor Protocol Number:
C22-11236

Filter Results

Locations

Study status

Gender

Age

Study phase

Search Results 1-5 of 5 for

MYELOMATCH: A Screening Study To Assign People With Myeloid Cancer To A Treatment Study Or Standard Of Care Treatment Within MyeloMATCH (MyeloMATCH Screening Trial)

A Study Of CTX-712 In Relapsed/Refractory Acute Myeloid Leukemia And Higher Risk Myelodysplastic Syndromes

Study Of SX-682 Alone And In Combination With Oral Or Intravenous Decitabine In Subjects With Myelodysplastic Syndrome

Cell, Serum, and Buccal Bank for Patients with Chronic Myeloid Disorders and Acute Leukemia

Methylation And Chromatin Abnormalities In Myelodysplastic Syndromes And Chronic Myelomonocytic Leukemia.

Mayo Clinic Footer

Legal Conditions and Terms

Advertising

Reprint Permissions